|Bid||6.22 x 2200|
|Ask||6.32 x 800|
|Day's Range||6.18 - 6.47|
|52 Week Range||4.30 - 16.66|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 12, 1980|
|1y Target Est||34.00|
Subscribe to Yahoo Finance Plus to view Fair Value for AIKI
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.
Proposal for All-Cash Transaction Represents a 31% Premium to AIKI’s Most Recent Closing Price Urges the Board to Immediately Enter into Good Faith Discussions with the Investor and Work to Deliver a Meaningful Premium to AIKI’s Stockholders NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) (“AIKI” or the “Company”) beneficially owning approximately 3.8% of its common stock, today announced that he has sent a letter propos
Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido. Mr. Aldavero joins Dominari from Morgan Stanley where he was Associate Complex Manager overseeing one of the largest and most profitable business units at the venerable Wall St. firm.